VenatoRx Pharmaceuticals Receives FDA’s QIDP and Fast Track Designations for Development of its Lead Antibiotic Program

By WebmasterJanuary 3, 2018November 1st, 2024No Comments

VenatoRx Pharmaceuticals Receives FDA’s QIDP and Fast Track Designations for Development of its Lead Antibiotic Program

Previous PostServier and Treventis begin strategic research partnership in neurodegenerative diseases
Next PostJenrin Discovery's IND Application for Its Peripherally Restricted Cannabinoid-1 Receptor Inverse Agonist NASH Compound Was Cleared by the FDA to Begin Phase 1 Clinical Trials